DCP-LA

DCP-LA Suppliers list
Company Name: Foshan Heshuo Pharm technology Co., ltd  Gold
Tel: 15363639686
Email: heshuoyiyao@hotmail.com
Company Name: 3B Pharmachem (Wuhan) International Co.,Ltd.  
Tel: 18930552037
Email: 3bsc@sina.com
Company Name: MedChemexpress LLC  
Tel: 021-58955995
Email: sales@medchemexpress.cn
Company Name: Bide Pharmatech Ltd.  
Tel: 400-164-7117 18317119277
Email: product02@bidepharm.com
Company Name: Sichuan Wei Keqi Biological Technology Co., Ltd.  
Tel: 028-81700200 18116577057
Email: 3003855609@qq.com

DCP-LA manufacturers

  • DCP-LA
  • DCP-LA pictures
  • $209.00
  • 2026-07-27
  • CAS:28399-31-7
  • Purity:
  • Supply Ability: 10g
  • DCP-LA
  • DCP-LA pictures
  • 2026-06-30
  • CAS:28399-31-7
  • Min. Order: 1KG
  • Purity: 98%
  • Supply Ability: 1000kgs
DCP-LA Basic information
Product Name:DCP-LA
Synonyms:DCP-LA;2-[(2-pentylcyclopropyl)methyl]cyclopropaneoctanoic acid, 8-[2-(2-pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid, FR 236924;2-[(2-Pentylcyclopropyl)methyl]cyclopropaneoctanoicacid;FR 236924;8-[2-(2-pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid;Cyclopropaneoctanoic acid, 2-[(2-pentylcyclopropyl)methyl]-;DCP LA,DCPLA
CAS:28399-31-7
MF:C20H36O2
MW:308.5
EINECS:
Product Categories:
Mol File:28399-31-7.mol
DCP-LA Structure
DCP-LA Chemical Properties
Boiling point 417.0±13.0 °C(Predicted)
density 0.968±0.06 g/cm3(Predicted)
storage temp. 2-8°C
solubility DMSO: >2mg/mL
pka4.78±0.10(Predicted)
form oil
color clear
InChIInChI=1S/C20H36O2/c1-2-3-7-10-16-13-18(16)15-19-14-17(19)11-8-5-4-6-9-12-20(21)22/h16-19H,2-15H2,1H3,(H,21,22)
InChIKeyCONYTTFKIUJZOF-UHFFFAOYSA-N
SMILESC1(CCCCCCCC(O)=O)CC1CC1CC1CCCCC
Safety Information
WGK Germany 3
Storage Class11 - Combustible Solids
MSDS Information
DCP-LA Usage And Synthesis
UsesFR 236924 is a PKCε activator, which may be useful as therapeutic agents for the treatment of Alzheimer disease as lowered PKCε activator levels are assocaited with Aβ degradation (a hallmark of Alzheimer’s disease).
Biological Activityfr 236924 is a selective activator of pkc-ε [1].pkc is a monomeric ca2+- and phospholipid-dependent ser/thr protein kinase and plays an important role in growth factor-activated signaling and malignant transformation.fr 236924 (dcp-la) is a selective pkc-ε activator. in pc-12 cells, dcp-la (10 nm-100 μm) activated pkc in a concentration dependent way with the maximal effect at 100 nm. in the cell-free system, dcp-la (100 μm) significantly activated pkc-ε and exhibited >7-fold potency over other pkc isozymes (α,βi, βii, γ, δ, μ, η and ζ), suggesting that dcp-la was a selective pkc-ε activator. dcp-la exhibited the maximal effect on pkc-ε at 100 μm. the activation of pkc-ε induced by dcp-la (100 μm) was inhibited by dioleoyl-phosphatidylserine in a concentration dependent way, suggesting that dcp-la might bound to the phosphatidylserine binding site on pkc-ε. however, dioleoyl-phosphatidylserine increased dcp-la (100 μm)-induced pkc-ε activation in a concentration dependent way, suggesting a different activation mechanism [1]. in xenopus oocytes expressing α7 receptors, fr236924 (10 μm) induced a persistent increased α7 receptor responses to 144% via a pkc pathway. in rat hippocampal slices, fr236924 (10 nm to 10 μm) facilitated hippocampal neurotransmission [2].in the hippocampus of rats, fr236924 induced glutamate release and facilitated hippocampal synaptic transmission through pkc [3].
Biochem/physiol ActionsDCP-LA is a selective PKC-epsilon (PKC-ε) activator. In the in situ PKC assay with a reversed phase high-performance liquid chromatography, DCP-LA significantly activated PKC in PC-12 cells in a concentration (10 nM-100 μM)-dependent manner, with the maximal effect at 100 nM. DCP-LA has over a 7-fold greater potency for activation of PKC-ε over other PKC isozymes.
in vivo

DCP-LA (1 mg/kg; p.o.; once daily; 7 d) exhibits a protective effect against ischemic brain damage, decreasing cerebral cortical defect due to middle cerebral artery (MCA) occlusion in mouse model[3].

Animal Model:Middle cerebral artery (MCA) occlusion in mouse model (male CB-17 mice, 5-8 weeks old)[3]
Dosage:1 mg/kg
Administration:Oral gavage; once daily for 7 days; sacrificed mice on days 28
Result:Significantly diminished degraded area due to cerebral infarction, with the rescued area reaching 82%.
IC 50PKCε; CaMK II
references[1]. kanno t, yamamoto h, yaguchi t, et al. the linoleic acid derivative dcp-la selectively activates pkc-epsilon, possibly binding to the phosphatidylserine binding site. j lipid res, 2006, 47(6): 1146-1156.
[2]. tanaka a, nishizaki t. the newly synthesized linoleic acid derivative fr236924 induces a long-lasting facilitation of hippocampal neurotransmission by targeting nicotinic acetylcholine receptors. bioorg med chem lett, 2003, 13(6): 1037-1040.
[3]. yamamoto s, kanno t, nagata t, et al. the linoleic acid derivative fr236924 facilitates hippocampal synaptic transmission by enhancing activity of presynaptic alpha7 acetylcholine receptors on the glutamatergic terminals. neuroscience, 2005, 130(1): 207-213.
DCP-LA Preparation Products And Raw materials
Tag:DCP-LA(28399-31-7) Related Product Information
DCP-LA 10-methyloctadecanoic acid 5-Methylheptanoic acid 2-(2,2-dimethylcyclopropyl)acetic acid 3-isopropylglutaric acid 18-methyleicosanoic acid